UK's MHRA and Gates Foundation research medicine use in pregnancy
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) has been given a $360,000 grant by the Bill and Melinda Gates Foundation to support research into the safe use of medicine during pregnancy.
This research will help predict the need for adjusting a medicine’s dose during different trimesters of pregnancy to ensure effective and safe use for the health of the mother and baby.
Worldwide, data in this area remain limited, and new insights could potentially impact the health of pregnant women around the world. This would also give obstetricians further clarity on the optimal dose of a medicine, when treating pregnant patients, for whom use of a medicine is necessary.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze